We identified the involvement of CD8+ T cells in antitumor immunity during the process of tumor lymphatic metastasis and established an immune-feature-based three-gene-signature risk-scoring system to predict HNSCC prognosis. Here, CD8A is linked to head and neck squamous cell carcinoma.